Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study - Dimopoulos, M A; Moreau, P; Palumbo, A (Lancet Oncol, 2016)
. doi:10.1016/S1470-2045(15)00464-7